Assessing the risk of cervical neoplasia in the post-HPV vaccination era.

"CONFLICT OF INTEREST Matti Lehtinen, Ville N. Pimenoff, Belinda Nedjai, Karolina Louvanto, Lisanne Verhoef and Joakim Dillner have no conflicts of interest to declare. Mariam El‐Zein holds a patent related to the discovery “DNA methylation markers for early detection of cervical cancer” registered at the Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada (October 2018). Daniëlle A. M. Heideman is minority shareholder of Self‐screen B.V., a spin‐off company of VUmc; Self‐screen B.V. develops, manufactures and licenses high‐risk HPV and methylation marker assays for cervical cancer screening and hold patents of these tests. Martin Widschwendter is a shareholder of Sola Diagnostics GmbH, which holds an exclusive license to the intellectual property that protects the commercialization of the WID‐tests."

"FUNDING INFORMATION Matti Lehtinen and Joakim Dillner have received funding for their HPV vaccination studies through their employers from GSK Biologicals (ML) and Merck & Co. Inc (ML and JD)."